According to Richard Pascoe, president and CEO of Somaxon, Silenor the first sleep aid that hasn’t been deemed a controlled substance.
A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.
The Harvard Business Review recently published a list of 10 innovations poised to change the medical industry in 2010.
Corindus Vascular Robotics has developed a robotic system to improve percutaneous coronary intervention (PCI) placement and reduce health risks to both the patient and the physician.
The 2003 death of Three’s Company actor John Ritter created new awareness of aortic dissection, a condition that affects tens of thousands of Americans each year.
The recommendation caused a 64 percent jump in InterMune stock prices and fueled speculation that the Brisbane, Calif.-based company is ripe for acquisition.
Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs.
